Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The market for respiratory syncytial virus (rsv) therapeutics has experienced rapid expansion in its size over recent years. Forecasts indicate it will expand from $1.6 billion in 2024 to reach $2 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 24.6%. This historical growth is attributable to factors such as increased disease awareness, significant advancements in virology, the particular vulnerability of pediatric populations, occurrences of epidemic outbreaks, and progress in vaccine development.
The respiratory syncytial virus (rsv) therapeutics market size is projected to experience substantial growth over the upcoming years. By 2029, it is anticipated to reach “$4.58 billion”, showing a compound annual growth rate (CAGR) of 23.1%. This growth during the forecast period is fueled by advancements in biologic therapies, the emergence of new antivirals, increased attention on the elderly demographic, widespread maternal immunization strategies, and collaborative global research efforts. Key trends expected during this period involve enhancements in monoclonal antibodies, the development of nasal vaccines and their delivery systems, the rise of combination therapies, innovative drug delivery methods, and an expansion of home-based treatment solutions.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
Which Drivers Are Impacting The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The escalating prevalence of respiratory syncytial virus (RSV) infection is significantly driving the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV is a common respiratory illness that can lead to mild to severe infections, particularly affecting newborns, young children, elderly adults, and individuals with weakened immune systems. The increasing number of RSV infections necessitates the development of innovative treatments to address the growing demand and alleviate the severity of RSV-related complications. For instance, in September 2023, the Centres for Disease Control and Prevention, a US-based national public health agency, indicated a notable increase in RSV-associated hospitalization rates among children under 4 years, rising from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Consequently, the rising prevalence of RSV infection is a primary factor propelling the growth of the respiratory syncytial virus (RSV) therapeutics market.
What Are The Different Segment Classifications Within The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The respiratory syncytial virus (rsv) therapeuticsmarket covered in this report is segmented –
1) By Drug: Palivizumab; Ribavirin; Other Drugs
2) By Treatment: Immune Prophylaxis; Supportive Care; Antiviral Medications
3) By Dosage Form: Oral; Injectable; Other Dosage Forms
4) By Patient Type: Pediatrics; Adults
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir; Nitazoxanide; Other Experimental Or Off-Label Treatments
Which Competitive Trends Are Defining The Respiratory Syncytial Virus (RSV) Therapeutics Market Structure?
A notable trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market is the development of new drugs and vaccines offering enhanced efficacy. Major companies operating within the respiratory syncytial virus (RSV) therapeutics market are concentrating on creating novel drugs and vaccines to sustain their position. For example, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, secured approval from the Food and Drug Administration, a US-based federal agency tasked with safeguarding and promoting public health, for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is administered to prevent lower respiratory tract illness caused by RSV in individuals aged 60 and older. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins engineered to maximize immunity to both RSV A and B varieties, and it has demonstrated clinical safety and productivity.
Which Major Industry Participants Are Leading The Respiratory Syncytial Virus (RSV) Therapeutics Market Growth?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Respiratory Syncytial Virus (RSV) Therapeutics Industry?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Respiratory Syncytial Virus (RSV) Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp
Browse Through More Reports Similar to the Global Respiratory Syncytial Virus (RSV) Therapeutics Market 2025, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Respiratory Disposables Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Devices And Equipment Therapeutic Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model